Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 2571

1.

Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease.

Parkinson Study Group CALM Cohort Investigators.

Arch Neurol. 2009 May;66(5):563-70. doi: 10.1001/archneur.66.1.nct90001.

PMID:
19433655
2.

Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.

Holloway RG, Shoulson I, Fahn S, Kieburtz K, Lang A, Marek K, McDermott M, Seibyl J, Weiner W, Musch B, Kamp C, Welsh M, Shinaman A, Pahwa R, Barclay L, Hubble J, LeWitt P, Miyasaki J, Suchowersky O, Stacy M, Russell DS, Ford B, Hammerstad J, Riley D, Standaert D, Wooten F, Factor S, Jankovic J, Atassi F, Kurlan R, Panisset M, Rajput A, Rodnitzky R, Shults C, Petsinger G, Waters C, Pfeiffer R, Biglan K, Borchert L, Montgomery A, Sutherland L, Weeks C, DeAngelis M, Sime E, Wood S, Pantella C, Harrigan M, Fussell B, Dillon S, Alexander-Brown B, Rainey P, Tennis M, Rost-Ruffner E, Brown D, Evans S, Berry D, Hall J, Shirley T, Dobson J, Fontaine D, Pfeiffer B, Brocht A, Bennett S, Daigneault S, Hodgeman K, O'Connell C, Ross T, Richard K, Watts A; Parkinson Study Group.

Arch Neurol. 2004 Jul;61(7):1044-53. Erratum in: Arch Neurol. 2005 Mar;62(3):430.

PMID:
15262734
3.
4.

Pramipexole in levodopa-treated Parkinson disease patients of African, Asian, and Hispanic heritage.

Parkinson Study Group.

Clin Neuropharmacol. 2007 Mar-Apr;30(2):72-85.

PMID:
17414939
6.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
7.

Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.

Hauser RA, Schapira AH, Rascol O, Barone P, Mizuno Y, Salin L, Haaksma M, Juhel N, Poewe W.

Mov Disord. 2010 Nov 15;25(15):2542-9. doi: 10.1002/mds.23317.

PMID:
20669317
8.

The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.

Leentjens AF, Koester J, Fruh B, Shephard DT, Barone P, Houben JJ.

Clin Ther. 2009 Jan;31(1):89-98. doi: 10.1016/j.clinthera.2009.01.012. Erratum in: Clin Ther. 2009 Mar;31(3):677.

PMID:
19243709
9.

Factors associated with the development of motor fluctuations and dyskinesias in Parkinson disease.

Hauser RA, McDermott MP, Messing S.

Arch Neurol. 2006 Dec;63(12):1756-60.

PMID:
17172616
11.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
12.

Impact of pramipexole on the onset of levodopa-related dyskinesias.

Constantinescu R, Romer M, McDermott MP, Kamp C, Kieburtz K; CALM-PD Investigators of the Parkinson Study Group.

Mov Disord. 2007 Jul 15;22(9):1317-9.

PMID:
17534955
14.

Identification of motor and nonmotor wearing-off in Parkinson's disease: comparison of a patient questionnaire versus a clinician assessment.

Stacy M, Bowron A, Guttman M, Hauser R, Hughes K, Larsen JP, LeWitt P, Oertel W, Quinn N, Sethi K, Stocchi F.

Mov Disord. 2005 Jun;20(6):726-33.

PMID:
15719426
15.

Bilateral subthalamotomy in Parkinson's disease: initial and long-term response.

Alvarez L, Macias R, Lopez G, Alvarez E, Pavon N, Rodriguez-Oroz MC, Juncos JL, Maragoto C, Guridi J, Litvan I, Tolosa ES, Koller W, Vitek J, DeLong MR, Obeso JA.

Brain. 2005 Mar;128(Pt 3):570-83. Epub 2005 Feb 2.

PMID:
15689366
16.
17.

Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial.

Shoulson I, Oakes D, Fahn S, Lang A, Langston JW, LeWitt P, Olanow CW, Penney JB, Tanner C, Kieburtz K, Rudolph A; Parkinson Study Group.

Ann Neurol. 2002 May;51(5):604-12.

PMID:
12112107
18.

Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life.

Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR.

Mov Disord. 2009 Jul 30;24(10):1468-74. doi: 10.1002/mds.22596.

PMID:
19425079
19.

[Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].

Jost WH, Klasser M, Reichmann H.

Fortschr Neurol Psychiatr. 2008 Oct;76(10):594-9. doi: 10.1055/s-2008-1038249. Epub 2008 Oct 2. German.

PMID:
18833504
20.

Estrogen improves motor disability in parkinsonian postmenopausal women with motor fluctuations.

Tsang KL, Ho SL, Lo SK.

Neurology. 2000 Jun 27;54(12):2292-8.

PMID:
10881255

Supplemental Content

Support Center